Premium
Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2
Author(s) -
Zhou Hong,
Fang Yan,
Xu Tao,
Ni WeiJian,
Shen AiZong,
Meng XiaoMing
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15092
Subject(s) - covid-19 , coronavirus , drug development , medicine , identification (biology) , computational biology , virus , drug discovery , drug , bioinformatics , virology , biology , disease , pharmacology , infectious disease (medical specialty) , pathology , outbreak , botany
As of April 9, 2020, a novel coronavirus (SARS‐CoV‐2) had caused 89,931 deaths and 1,503,900 confirmed cases worldwide, which indicates an increasingly severe and uncontrollable situation. Initially, little was known about the virus. As research continues, we now know the genome structure, epidemiological and clinical characteristics, and pathogenic mechanisms of SARS‐CoV‐2. Based on this knowledge, potential targets involved in the processes of virus pathogenesis need to be identified, and the discovery or development of drugs based on these potential targets is the most pressing need. Here, we have summarized the potential therapeutic targets involved in virus pathogenesis and discuss the advances, possibilities, and significance of drugs based on these targets for treating SARS‐CoV‐2. This review will facilitate the identification of potential targets and provide clues for drug development that can be translated into clinical applications for combating SARS‐CoV‐2.